KMT2A and acute leukemia: There are at least six distinct menin‐KMT2A inhibitors that are currently being evaluated in clinical trials as first‐ and second‐line monotherapy for acute leukemias (DSP‐5336, BMF‐219, DS‐1594, JNJ‐75276617, ziftomenib, and revumenib) [80].